Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.

There has been an increasing focus on drug induced QT prolongation including research on drug development and QT prolongation, following the removal of drugs due to torsades de pointes (TdP). Although this has improved our understanding of drug-induced QT prolongation there has been much less research aimed at helping clinicians assess risk in individual patients with drug induced QT prolongation. This review will focus on assessment of drug-induced QT prolongation in clinical practice using a simple risk assessment approach. Accurate measurement of the QT interval is best done manually, and not using the measurement of standard ECG machines. Correction for heart rate (HR) using correction formulae such as Bazett's is often inaccurate. These formulae underestimate and overestimate the duration of cardiac repolarization at low and high heart rates, respectively. Numerous cut-offs have been suggested as an indicator of an abnormal QT, but are problematic in clinical practice. An alternative approach is the QT nomogram which is a plot of QT vs. HR. The nomogram has an 'at risk' line and QT-HR pairs above this line have been shown in a systematic study to be associated with TdP and the line is more sensitive and specific than Bazett's QTc of 440 ms or 500 ms. Plotting the QT-HR pair for patients on drugs suspected or known to cause QT prolongation allows assessment of the QT interval based on normal population QT variability. This risk assessment then allows the safer commencement of drugs therapeutically or management of drug induced effects in overdose.

[1]  D. Rowlands Graphical representation of QT rate correction formulae: an aid facilitating the use of a given formula and providing a visual comparison of the impact of different formulae. , 2012, Journal of electrocardiology.

[2]  A. Dunlop,et al.  Individual patient assessment of methadone-induced QT prolongation with digital holter recording. , 2012, Journal of addiction medicine.

[3]  S. Duffull,et al.  Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. , 2012, British journal of clinical pharmacology.

[4]  G. Isbister,et al.  Digital Holter measurement of QT prolongation in ziprasidone overdose , 2011, Clinical toxicology.

[5]  G. Isbister,et al.  Prediction of Torsade de Pointes From the QT Interval: Analysis of a Case Series of Amisulpride Overdoses , 2011, Clinical pharmacology and therapeutics.

[6]  B. Dumotier,et al.  Drug-Induced QTC Prolongation Dangerously Underestimates Proarrhythmic Potential: Lessons From Terfenadine , 2011, Journal of cardiovascular pharmacology.

[7]  T. Nakayama,et al.  Automated versus Manual Measurement of the QT Interval and Corrected QT Interval , 2011, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[8]  N. Buckley,et al.  Enhanced elimination in acute barbiturate poisoning – A systematic review , 2011, Clinical toxicology.

[9]  W. Waring,et al.  Evaluation of a QT nomogram for risk assessment after antidepressant overdose. , 2010, British journal of clinical pharmacology.

[10]  Rui Wang,et al.  The cardiotoxicity of macrolides: a systematic review. , 2010, Die Pharmazie.

[11]  G. Isbister,et al.  Risperidone Overdose Causes Extrapyramidal Effects But Not Cardiac Toxicity , 2010, Journal of clinical psychopharmacology.

[12]  S. Duffull,et al.  Amisulpride Overdose Is Frequently Associated With QT Prolongation and Torsades de Pointes , 2010, Journal of clinical psychopharmacology.

[13]  M. Gollob,et al.  The genetic and clinical features of cardiac channelopathies. , 2010, Future cardiology.

[14]  B. Stricker,et al.  Drug- and non-drug-associated QT interval prolongation. , 2010, British journal of clinical pharmacology.

[15]  B. Stokes,et al.  Inter-rater reliability of manual QT measurement and prediction of abnormal QT,HR pairs , 2009, Clinical toxicology.

[16]  M J Ackerman,et al.  QTc: how long is too long? , 2009, British Journal of Sports Medicine.

[17]  L. Cubeddu Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance , 2009, Current cardiology reviews.

[18]  G. Isbister Electrocardiogram changes and arrhythmias in venlafaxine overdose. , 2009, British journal of clinical pharmacology.

[19]  Thomas Lumley,et al.  Common variants at ten loci influence QT interval duration in the QTGEN Study , 2009, Nature Genetics.

[20]  M. Krantz,et al.  QTc Interval Screening in Methadone Treatment , 2009, Annals of Internal Medicine.

[21]  A. Bhalla,et al.  Cardiac abnormalities in acute organophosphate poisoning , 2009, Clinical toxicology.

[22]  Arthur A M Wilde,et al.  Accurate electrocardiographic assessment of the QT interval: teach the tangent. , 2008, Heart rhythm.

[23]  G K Isbister,et al.  Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. , 2007, QJM : monthly journal of the Association of Physicians.

[24]  A. D. Wilson,et al.  Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. , 2007, British journal of clinical pharmacology.

[25]  G. Jensen,et al.  Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen , 2007, Heart.

[26]  Stefano Severi,et al.  Calcium and potassium changes during haemodialysis alter ventricular repolarization duration: in vivo and in silico analysis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  M. Malik,et al.  Precision of QT Interval Measurement by Advanced Electrocardiographic Equipment , 2006, Pacing and clinical electrophysiology : PACE.

[28]  S. Duffull,et al.  Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose , 2006, Intensive Care Medicine.

[29]  Lena E Friberg,et al.  Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. , 2006, British journal of clinical pharmacology.

[30]  A. Hofman,et al.  Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. , 2006, Journal of the American College of Cardiology.

[31]  R. Woosley,et al.  QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system , 2005, Pharmacoepidemiology and drug safety.

[32]  V. Piotrovsky,et al.  Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation , 2005, The AAPS Journal.

[33]  A. C. Hunt Accuracy of popular automatic QT Interval algorithms assessed by a 'Gold Standard' and comparison with a Novel method: computer simulation study , 2005, BMC cardiovascular disorders.

[34]  D. Levy,et al.  QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: The Framingham Heart Study. , 2005, Heart rhythm.

[35]  Kimberly Crimin,et al.  Dynamic Beat-to-Beat Modeling of the QT-RR Interval Relationship: Analysis of QT Prolongation during Alterations of Autonomic State versus Human Ether a-go-go-Related Gene Inhibition , 2005, Journal of Pharmacology and Experimental Therapeutics.

[36]  Peter W Macfarlane,et al.  A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. , 2004, Journal of electrocardiology.

[37]  A. Edefonti,et al.  Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  I. Whyte,et al.  Quetiapine poisoning: a case series. , 2003, Annals of Emergency Medicine.

[39]  G. Isbister,et al.  Bupropion Overdose: QTc Prolongation and its Clinical Significance , 2003, The Annals of pharmacotherapy.

[40]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[41]  A. Mangoni,et al.  Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis. , 2003, Age and ageing.

[42]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[43]  Marek Malik,et al.  Individual patterns of QT/RR relationship. , 2002, Cardiac electrophysiology review.

[44]  P. Davey How to correct the QT interval for the effects of heart rate in clinical studies. , 2002, Journal of pharmacological and toxicological methods.

[45]  R. Shah Drug‐induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity , 2002, Fundamental & clinical pharmacology.

[46]  A. Camm,et al.  Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval , 2002, Heart.

[47]  Marek Malik,et al.  The Imprecision in Heart Rate Correction May Lead to Artificial Observations of Drug Induced QT Interval Changes , 2002, Pacing and clinical electrophysiology : PACE.

[48]  D. Wysowski,et al.  Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.

[49]  M. Sanguinetti,et al.  Molecular and Cellular Mechanisms of Cardiac Arrhythmias , 2001, Cell.

[50]  R. Passman,et al.  Effects of Sex and Age on Electrocardiographic and Cardiac Electrophysiological Properties in Adults , 2001, Pacing and clinical electrophysiology : PACE.

[51]  J. Camm,et al.  Risk of torsades de pointes with non-cardiac drugs , 2000, BMJ : British Medical Journal.

[52]  P. Davey,et al.  QT interval measurement: Q to TApex or Q to TEnd? , 1999, Journal of internal medicine.

[53]  A. Cupisti,et al.  Potassium Removal Increases the QTc Interval Dispersion during Hemodialysis , 1999, Nephron.

[54]  B. Eckert,et al.  Hypoglycaemia leads to an increased QT interval in normal men. , 1998, Clinical physiology.

[55]  Morrison Hodges,et al.  Rate Correction of the QT Interval , 1997 .

[56]  P. Schwartz,et al.  Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. , 1997, European heart journal.

[57]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .

[58]  G. Hill,et al.  Diuretic-induced hypokalaemia inducing torsades de pointes , 1995, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[59]  T. Davis,et al.  Dynamic assessment of the electrocardiographic QT interval during citrate infusion in healthy volunteers. , 1995, British heart journal.

[60]  P Jaillon,et al.  Rate-corrected QT interval: techniques and limitations. , 1993, The American journal of cardiology.

[61]  A. Pelech,et al.  ASTEMIZOLE-INDUCED TORSADE DE POINTES , 1988, The Lancet.

[62]  B. Surawicz,et al.  The Measurement of the Q‐T Interval of the Electrocardiogram , 1952, Circulation.

[63]  F. Marchlinski,et al.  Mechanisms of cardiac arrhythmias. , 2012, Revista espanola de cardiologia.

[64]  A. Vale,et al.  Quetiapine overdose: predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal , 2009 .

[65]  R. Shah Drugs, QTc Interval Prolongation and Final ICH E14 Guideline , 2005, Drug safety.

[66]  David Zeltser,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[67]  A J Camm,et al.  Evaluation of Drug-Induced QT Interval Prolongation , 2001, Drug safety.

[68]  P. Gajwani,et al.  QT interval prolongation associated with quetiapine (Seroquel) overdose. , 2000, Psychosomatics.

[69]  J. Weiss,et al.  Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. , 1996, Journal of the American College of Cardiology.